Although Parkinson’s is thought of primarily as a movement disorder, memory is frequently affected, and this interferes with quality of life. This research aims to find tests — so called “biomarkers” — that are critical for developing new therapies to slow or even prevent memory loss. A pathway regulating an important type of brain lipids (fats in nerve cell membranes), termed sphingolipids, appears abnormal in Parkinson’s and will be monitored in blood. The goal is to develop a test for a “bad sphingolipid” useful for accelerating the development of medications to halt memory decline in patients.

Who can participate?

  • Patients with Parkinson’s disease and memory problems
  • Patients with dementia with Lewy bodies
  • Healthy controls

What does it involve?

Four visits over two years

  • Clinical assessments
  • Questionnaires
  • Blood draws

Parking will be validated. Compensation for optional CSF collection (once per year) is $200.

Interested in learning more?

Contact Yuliya Kuras, PhD: (857) 307-5424 or